Opioid Dependence
📧 Sign up to get email alerts when something new happens for Opioid Dependence.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-01Clinical Trial Update: Collaborative Care for Opioid Dependence And Pain Pilot Study [NA]
A pilot study investigating collaborative care for individuals with opioid dependence and chronic pain was terminated, with results posted i…
-
CLINICAL_TRIALS trial_result · 2024-02-02Clinical Trial Update: Facilitating Rapid Naltrexone Initiation [Phase 3]
Phase 3 clinical trial update on facilitating rapid initiation of naltrexone for opioid dependence; status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery [Phase 2]
A Phase 2 trial evaluating perioperative ketamine in opioid-tolerant patients undergoing lumbar spine surgery was terminated with results po…
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Feasibility and Preliminary Efficacy of an Opioid Stewardship Program in Hospitalized Patients With Chronic Pain [NA]
Feasibility and preliminary efficacy data from a completed clinical trial evaluating an opioid stewardship program in hospitalized patients …
-
FDA approval · 2023-12-15FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)
The FDA approved a supplemental application for Suboxone (buprenorphine hydrochloride/naloxone hydrochloride) from Indivior Inc., authorizin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries, Inc.'s supplemental application for a buprenorphine and naloxone product. The approval pertains …
-
FDA approval · 2023-09-12FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
The FDA approved a supplemental application for SUBLOCADE (buprenorphine) from Indivior Inc., updating the product labeling as part of a sup…
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: Remote Observed Dosing of Suboxone to Improve Clinical Practice [Phase 1, Phase 2]
A phase 1/2 trial evaluating remote observed dosing of Suboxone (buprenorphine/naloxone) to inform clinical practice for opioid-use disorder…
-
FDA approval · 2023-06-07FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Actavis Pharma’s generic buprenorphine/naloxone product for the treatment of opioid dependence. …
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: Treatment for Opioid Dependent Offenders [Phase 2, Phase 3]
Phase 2/3 trial update for a treatment targeting opioid dependence; study completed.
-
CLINICAL_TRIALS trial_result · 2023-03-27Clinical Trial Update: Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder [EARLY_Phase 1]
A Phase 1 early trial update for re-entry XR-NTX in rural individuals with opioid use disorder has completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Buprenorphine Treatment for Opioid Dependence [Phase 3]
A Phase 3 clinical trial investigating buprenorphine treatment for opioid dependence has completed.
-
CLINICAL_TRIALS research · 2023-02-10Clinical Trial Update: Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II [NA]
Clinical trial update on improving effective contraceptive use among women maintained on opioids; status completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-01-12Clinical Trial Update: Biomarkers of Injectable Extended Release Naltrexone Treatment [Phase 4]
Phase 4 trial update exploring biomarkers of injectable extended-release naltrexone in heroin and opioid dependence.
-
FDA approval · 2022-12-16FDA Approved: BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM — Supplemental Application (Alvogen Inc.)
FDA approved a supplemental application for the generic buprenorphine and naloxone sublingual film from Alvogen Inc., authorizing market aut…
-
CLINICAL_TRIALS trial_result · 2022-12-15Clinical Trial Update: Comparing Two Training Methods for Opioid Wizard [NA]
A completed clinical trial comparing two training methods related to opioid use disorder/ opioid dependence; results posted in 2022.
-
FDA approval · 2022-09-30FDA Approved: VIVITROL — Supplemental Application (Alkermes, Inc.)
FDA approved a supplemental application for VIVITROL (naltrexone) by Alkermes, Inc.
-
CLINICAL_TRIALS trial_result · 2022-08-08Clinical Trial Update: Medical Management of Sleep Disturbance During Opioid Tapering [Phase 2]
Phase 2 trial evaluating medical management of sleep disturbance during opioid tapering in opioid dependence/withdrawal.
-
FDA approval · 2022-06-17FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
The FDA approved a supplemental application for ZUBSOLV (buprenorphine hydrochloride and naloxone hydrochloride) by Orexo US, Inc., updating…
-
FDA approval · 2022-06-14FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's supplemental application for a buprenorphine HCl and naloxone HCl product, providing a generic opt…
-
FDA approval · 2022-05-03FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma's supplemental application for a buprenorphine and naloxone product (generic Suboxone) under ANDA, enabling …
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept [Phase 4]
Phase 4 pilot trial comparing XRB versus SLB in jail and at re-entry for opioid dependence; completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction [Phase 2]
Exploratory dose-ranging Phase 2 trial update for APH-1501 in opioid addiction, status not specified.
-
CLINICAL_TRIALS trial_result · 2021-06-07Clinical Trial Update: The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis [Phase 4]
Phase 4 clinical trial evaluating continuous sub-fascial bupivacaine infusion and lidocaine patches for analgesia in post-cesarean patients …
-
FDA approval · 2021-03-04FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s supplemental application for buprenorphine and naloxone, authorizing an updated approval for this pr…